| We advocate on behalf of patients with mutual health insurance funds. | 의학 연구
> 의학 연구 | 규제 파트너십
> 규제 기관과의 협력 | 100 | National | Rarely | 115057856231 |
| Eligible to the EMA [European Medicines Agency] and invited to meetings and events, been part of regulatory evaluations. Member of EU HTA [Health Technology Assessment] stakeholder forum. | 신경퇴행성
> 헌팅턴병 | 규제 파트너십
> 규제 기관과의 협력 | Do not know | International | Sometimes | 119075658991 |
| Drug Reimbursement Committee [Commissie Terugbetaling Geneesmiddelen – Drug Reimbursement Committee] via VPP [Vlaams Patiëntenplatform - Flemish Patients’ Platform]. | 류마티스성
> 류마티스 질환: 대부분의 유형 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 10,000 | Regional | Sometimes | 114996669704 |
| Providing information to the organisation that represents us in CTG [College Tarieven Gezondheidszorg - Healthcare Tariffs Board] reimbursement consultations concerning a new medicine. | 환자 교육
> 환자 정보 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 1,000 | Regional | Sometimes | 115028426381 |
| Through the Luss [Ligue des Usagers des Services de Santé – League of Health Service Users], which brings together several patient associations and has a member sitting on the Drug Reimbursement Committee at the INAMI [Institut National d'Assurance Maladie-Invalidité – National Institute for Health and Disability Insurance]. | 혈액
> 겸상 적혈구 질환 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | Do not know | National | Rarely | 115028443749 |
| FAGG [Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten – Federal Agency for Medicines and Health Products], KCE [Federaal Kenniscentrum voor de Gezondheidszorg – Belgian Health Care Knowledge Centre], and RIZIV [Rijksinstituut voor Ziekte- en Invaliditeitsverzekering – National Institute for Health and Disability Insurance]/CTG [Commissie Tegemoetkoming Geneesmiddelen – Drug Reimbursement Committee]. | 류마티스성
> 류마티스 질환: 대부분의 유형 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | We do not communicate with patients directly | Regional | Sometimes | 115034595480 |
| Completed several CTG [Commissie Toekenning Geneesmiddelen – Medicine Allocation Committee] dossiers. | 암
> 암: 폐 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 1,000 | National | Sometimes | 115036954847 |
| Input from the patient organisation on reimbursement dossiers for new medications (via an extensive questionnaire). | 암
> 암: 폐 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 1,000 | Regional | Sometimes | 115039053506 |
| Expert assessments in support of drug reimbursement decisions. | 신경퇴행성
> 치매 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | Do not know | Regional | Sometimes | 115043013133 |
| We provide advisory input through VPP [Vlaams Patiëntenplatform – Flemish Patient Platform] and, on occasion, in response to questionnaires issued by RIZIV [Rijksinstituut voor Ziekte- en Invaliditeitsverzekering – National Institute for Health and Disability Insurance]. | 알레르기
> 천식, 알레르기, 아토피 피부염, 습진 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | Do not know | National | Sometimes | 115043032741 |
| Advisory board of RIZIV [Rijksinstituut voor Ziekte- en Invaliditeitsverzekering – National Institute for Health and Disability Insurance] in connection with applications for reimbursement modalities for new medicines. | 출혈
> 출혈 장애: 대부분의 유형 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 5,000 | National | Rarely | 115049435993 |
| We participate in stakeholder engagement sessions organised by Pharma.be and FAGG [Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten – Federal Agency for Medicines and Health Products]. | 혈액
> 혈액 질환: ITP | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 100 | National | Sometimes | 115021567311 |
| FAGG [Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten – Federal Agency for Medicines and Health Products], KCE [Federaal Kenniscentrum voor de Gezondheidszorg – Belgian Health Care Knowledge Centre], and RIZIV [Rijksinstituut voor Ziekte- en Invaliditeitsverzekering – National Institute for Health and Disability Insurance]/CTG [Commissie Tegemoetkoming Geneesmiddelen – Drug Reimbursement Committee]. | 류마티스성
> 류마티스 질환: 대부분의 유형 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | We do not communicate with patients directly | Regional | Sometimes | 115034595480 |
| INAMI [Institut National d'Assurance Maladie-Invalidité – National Institute for Health and Disability Insurance], Minister of Health. | 암
> 암: 혈액 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 1,000 | National | Regularly | 115043127768 |
| EMA [European Medicines Agency] PCWP [Patients' and Consumers' Working Party] Forum at EU Parliament activities in our members' countries. | 면역
> 면역 저하 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | Over 100,000 | International | Regularly | 119074504996 |
| Eligible to the EMA [European Medicines Agency] and invited to meetings and events, been part of regulatory evaluations. Member of EU HTA [Health Technology Assessment] stakeholder forum. | 신경퇴행성
> 헌팅턴병 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | Do not know | International | Sometimes | 119075658991 |
| Drug Reimbursement Committee [Commissie Terugbetaling Geneesmiddelen – Drug Reimbursement Committee] via VPP [Vlaams Patiëntenplatform - Flemish Patients’ Platform]. | 류마티스성
> 류마티스 질환: 대부분의 유형 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 10,000 | Regional | Sometimes | 114996669704 |
| Via the VPP [Vlaams Patiënten Platform – Flemish Patients' Platform] on behalf of Alnylam Pharmaceuticals. | 신경퇴행성
> 아밀로이드증 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 1,000 | National | Sometimes | 114996917912 |
| In its newsletter No. 71 of November 2024, BCC [Belgian Brain Council - Conseil Belge du Cerveau] expressed its support for the statement issued by the Alzheimer Europe association in response to the EMA [European Medicines Agency]'s refusal to grant a marketing authorisation for Leqembi (lecanemab) for the treatment of mild cognitive impairment (memory and thinking disorders). | 정신 건강
> 정신 건강: 대부분의 상태 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 1,000 | International | Sometimes | 115006691079 |
| Providing information to the organisation that represents us in CTG [College Tarieven Gezondheidszorg - Healthcare Tariffs Board] reimbursement consultations concerning a new medicine. | 환자 교육
> 환자 정보 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 1,000 | Regional | Sometimes | 115028426381 |
| By being a member of umbrella organisations. | 류마티스성
> 경피증 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 100 | National | Sometimes | 115033503861 |
| By being a member of umbrella organisations. | 류마티스성
> 경피증 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 100 | National | Sometimes | 115033503861 |
| Via VPP [Vlaams Patiëntenplatform – Flemish Patients' Platform]. | 암
> 암: 드문 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 100 | Regional | Rarely | 115043019020 |
| We provide advisory input through VPP [Vlaams Patiëntenplatform – Flemish Patient Platform]. | 알레르기
> 천식, 알레르기, 아토피 피부염, 습진 | 규제 파트너십
> 다른 의료 지지자들과 함께 | Do not know | National | Sometimes | 115043032741 |
| We provide advisory input through VPP [Vlaams Patiëntenplatform – Flemish Patient Platform]. | 알레르기
> 천식, 알레르기, 아토피 피부염, 습진 | 규제 파트너십
> 다른 의료 지지자들과 함께 | Do not know | National | Sometimes | 115043032741 |
| Through our association OntmoetPijn, we are members of the Vlaamse Pijnliga [Flemish Pain League] and use that platform to advocate on behalf of people living with chronic pain. | 신경학적
> 통증 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 100 | Regional | Sometimes | 115046494165 |
| We are a member of VPP [Vlaams Patiëntenplatform – Flemish Patients' Platform]. They advocate on our behalf. | 신경근
> 신경근육 질환: 대부분의 유형 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 1,000 | Regional | No | 115055397447 |
| EMA [European Medicines Agency] PCWP [Patients' and Consumers' Working Party] Forum at EU Parliament activities in our members' countries. | 면역
> 면역 저하 | 규제 파트너십
> 다른 의료 지지자들과 함께 | Over 100,000 | International | Regularly | 119074504996 |
| Affiliated with the Vlaams Patiëntenplatform [Flemish Patients' Platform] and Kom op Tegen Kanker [Stand Up to Cancer]. | 암
> 암: 유방 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 1,000 | Regional | Rarely | 115020713219 |
| Advisory board member at Kom op tegen Kanker [Kom op tegen Kanker – Fight Against Cancer]. | 암
> 암: 유방 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 100 | Regional | Rarely | 115036847346 |
| Providing advisory input on legislative work concerning involuntary psychiatric admissions [Belgium]. | 정신 건강
> 정신 건강: 돌봄 제공자, 가족, 친구 | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | 1,000 | Regional | Regularly | 115056630689 |
| Regional discussion on the cardiovascular prevention plan, with outreach to municipalities and CPAS [Centre Public d'Action Sociale – Public Centre for Social Welfare]. | 심혈관
> 심혈관: 대부분의 유형 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | 100,000 | National | Regularly | 115042996911 |
| Roundtable discussions in parliament and visits to ministers’ offices. | 암
> 암: 부인과 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | 1,000 | National | Rarely | 115045208576 |
| EMA [European Medicines Agency] PCWP [Patients' and Consumers' Working Party] Forum at EU Parliament activities in our members' countries. | 면역
> 면역 저하 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | Over 100,000 | International | Regularly | 119074504996 |
| Hearing before the Belgian Senate – 24 November 2023. | 혈액
> 겸상 적혈구 질환 | 정책 및 법률에 영향 미치기
> 의회 의원 및 정치 지도자 동원 | Do not know | National | Sometimes | 115035784218 |
| Providing advisory input on legislative work concerning involuntary psychiatric admissions. | 정신 건강
> 정신 건강: 돌봄 제공자, 가족, 친구 | 정책 및 법률에 영향 미치기
> 환자 보호 법안 및 권리 옹호 | 1,000 | Regional | Regularly | 115056630689 |
| In its newsletter No. 71 of November 2024, BCC [Belgian Brain Council - Conseil Belge du Cerveau] expressed its support for the statement issued by the Alzheimer Europe association in response to the EMA [European Medicines Agency]'s refusal to grant a marketing authorisation for Leqembi (lecanemab) for the treatment of mild cognitive impairment (memory and thinking disorders). | 정신 건강
> 정신 건강: 대부분의 상태 | 정책 및 법률에 영향 미치기
> 의료 서비스의 장벽/이상 현상 해결 | 1,000 | International | Sometimes | 115006691079 |
| A legislative anomaly exists with regard to the funding of self-catheterisation for individuals residing in a residential care facility. | 신경학적
> 다발성 경화증 | 정책 및 법률에 영향 미치기
> 의료 서비스의 장벽/이상 현상 해결 | 5,000 | Regional | Rarely | 115028407747 |
| … certain medications are reimbursed for women with breast cancer but not for men with the same condition. | 암
> 암(남성): 유방 | 정책 및 법률에 영향 미치기
> 의료 서비스의 장벽/이상 현상 해결 | 100 | Regional | Sometimes | 115031895194 |
| We are calling for improved reimbursement of our medications. | 위장관
> IBD | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 100,000 | Regional | Sometimes | 115020038862 |
| Ensuring reimbursement for specific medicines. | 호흡기
> COPD | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 5,000 | Regional | Sometimes | 115029939063 |
| Through our association OntmoetPijn, we are a member of the Flemish Pain League, where we actively advocate on behalf of people living with chronic pain — including, for example, issues relating to the cost of medication. | 신경학적
> 통증 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 100 | Regional | Sometimes | 115046494165 |
| VPP [Vlaams Patiëntenplatform - Flemish Patients’ Platform] participates as a patient organisation in consultative platforms addressing key bottlenecks, such as reimbursement and temporary unavailability of medicines. Pricing policy is also covered within this remit. Through the ELZ [Eerstelijnszone – Primary Care Zone] P-Zon [Personen met een Zorg- en OndersteuningsNood - People with a Care and Support Need], we additionally ensure the patient voice is represented within the P-Zon cluster. | 신장
> 신장 질환 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 100 | Regional | Sometimes | 115055534359 |
| Request for medication reimbursement. | 암
> 암: 혈액 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 1,000 | Regional | Sometimes | 115057073683 |
| Completing the RIZIV [Rijksinstituut voor ziekte- en invaliditeitsverzekering – National Institute for Health and Disability Insurance] questionnaire in order to obtain reimbursement for medicines. | 호흡기
> COPD | 가격 책정 및 affordability 옹호
> 가격 검토 위원회 협상에 참여 | 5,000 | Regional | Sometimes | 114997831407 |
| An intervention was made in 2015 through the mutual health insurers at INAMI [Institut national d'assurance maladie-invalidité – National Institute for Health and Disability Insurance] to amend the reimbursement conditions for Imitrex SC [subcutaneous injection - used to quickly treat acute migraine attacks and cluster headaches in adults]. | 신경학적
> 편두통 | 가격 책정 및 affordability 옹호
> 가격 검토 위원회 협상에 참여 | 100 | National | Rarely | 115006822909 |
| Reimbursement applications for certain medicines through INAMI [Institut National d'Assurance Maladie-Invalidité – National Institute for Health and Disability Insurance]. | 류마티스성
> 루푸스 | 가격 책정 및 affordability 옹호
> 가격 검토 위원회 협상에 참여 | 100 | National | Regularly | 115029783188 |
| Advisory board of RIZIV [Rijksinstituut voor Ziekte- en Invaliditeitsverzekering – National Institute for Health and Disability Insurance] in connection with applications for reimbursement modalities for new medicines. | 출혈
> 출혈 장애: 대부분의 유형 | 가격 책정 및 affordability 옹호
> 가격 검토 위원회 협상에 참여 | 5,000 | National | Rarely | 115049435993 |
| VPP [Vlaams Patiëntenplatform - Flemish Patients’ Platform] participates as a patient organisation in consultative platforms addressing key bottlenecks, such as reimbursement and temporary unavailability of medicines. Pricing policy is also covered within this remit. Through the ELZ [Eerstelijnszone – Primary Care Zone] P-Zon [Personen met een Zorg- en OndersteuningsNood - People with a Care and Support Need], we additionally ensure the patient voice is represented within the P-Zon cluster [atient participation cluster within a Flemish primary-care network]. | 신장
> 신장 질환 | 가격 책정 및 affordability 옹호
> 가격 검토 위원회 협상에 참여 | 100 | Regional | Sometimes | 115055534359 |
| Recommendation submitted to the CTG [Commissie Tegemoetkoming Geneesmiddelen – Drug Reimbursement Committee] via a completed questionnaire: reimbursement of Buccolam for individuals with epilepsy aged 18 years and over. | 신경학적
> 간질 | 가격 책정 및 affordability 옹호
> 가격 검토 위원회 협상에 참여 | 1,000 | Regional | Sometimes | 115057861541 |
| Completing the RIZIV [Rijksinstituut voor ziekte- en invaliditeitsverzekering – National Institute for Health and Disability Insurance] questionnaire in order to obtain reimbursement for medicines. | 호흡기
> COPD | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 5,000 | Regional | Sometimes | 114997831407 |
| Medications that are essential for the provision of quality palliative care are reviewed by us and designated for mandatory availability in local pharmacies. | 만성
> 완화 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 1,000 | Regional | Sometimes | 115002049927 |
| Reimbursement applications for certain medicines through INAMI [Institut National d'Assurance Maladie-Invalidité – National Institute for Health and Disability Insurance]. | 류마티스성
> 루푸스 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 100 | National | Regularly | 115029783188 |
| Ensuring reimbursement for specific medicines. | 호흡기
> COPD | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 5,000 | Regional | Sometimes | 115029939063 |
| Equal treatment for women and men with breast cancer. Certain medications are reimbursed for women with breast cancer but not for men with the same condition. | 암
> 암(남성): 유방 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 100 | Regional | Sometimes | 115031895194 |
| HPV [Human Papillomavirus] vaccination reimbursed for boys up to the age of 18. | 암
> 암: HPV | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 1,000 | National | Sometimes | 115051943511 |
| VPP [Vlaams Patiëntenplatform - Flemish Patients’ Platform] participates as a patient organisation in consultative platforms addressing key bottlenecks, such as reimbursement and temporary unavailability of medicines. Pricing policy is also covered within this remit. Through the ELZ [Eerstelijnszone – Primary Care Zone] P-Zon [Personen met een Zorg- en OndersteuningsNood - People with a Care and Support Need], we additionally ensure the patient voice is represented within the P-Zon cluster. | 신장
> 신장 질환 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 100 | Regional | Sometimes | 115055534359 |
| Request for medication reimbursement. | 암
> 암: 혈액 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 1,000 | Regional | Sometimes | 115057073683 |
| Recommendation submitted to the CTG [Commissie Tegemoetkoming Geneesmiddelen – Drug Reimbursement Committee] via a completed questionnaire: reimbursement of Buccolam for individuals with epilepsy aged 18 years and over. | 신경학적
> 간질 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 1,000 | Regional | Sometimes | 115057861541 |
| [Advocate] for greater availability of well-maintained public restroom facilities, and for the establishment of a national Inflammatory Bowel Disease (IBD) awareness day. | 위장관
> IBD | 가격 책정 및 affordability 옹호
> 인식 제고 캠페인 참여 | 100,000 | Regional | Sometimes | 115020038862 |
| Medications that are essential for the provision of quality palliative care are reviewed by us and designated for mandatory availability in local pharmacies. | 만성
> 완화 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | Regional | Sometimes | 115002049927 |
| [Advocate] for greater availability of well-maintained public restroom facilities, and for the establishment of a national Inflammatory Bowel Disease (IBD) awareness day. | 위장관
> IBD | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 100,000 | Regional | Sometimes | 115020038862 |
| Reimbursement of PrEP [Pre-Exposure Prophylaxis] for community-based organisations. | 일반 건강
> 성 건강: 기타 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 100 | Regional | Sometimes | 115046432045 |
| HPV [Human Papillomavirus] vaccination reimbursed for boys up to the age of 18. | 암
> 암: HPV | 접근 경로 개선
> 더 넓은 백신 접근성을 위해 옹호하기 | 1,000 | National | Sometimes | 115051943511 |
| Our association is an active member of various associations and organisations that regularly participate in advisory committees on this topic [drug pricing] (e.g. RaDiOrg, Rare Disorders Belgium & ERN [European Reference Network] Transplantchild). | 희귀
> 희귀 질환: 아동/청소년 | 접근 경로 개선
> 희귀/초희귀 치료제 접근성 개선 | 100 | International | Sometimes | 115037392949 |
| Since the introduction of a patient advisory process for the CTG [College Tarieven Gezondheidszorg - Healthcare Tariffs Authority] procedure in early 2025, we have compiled a submission dossier on two occasions. | 희귀
> 낭포성 섬유증 | 근거 기반 환자 의견
> 환자 인사이트를 활용하여 의사 결정에 반영하세요 | 1,000 | National | Sometimes | 115005093988 |
| [Patient] expert assessments in support of drug reimbursement decisions. | 신경퇴행성
> 치매 | 근거 기반 환자 의견
> 환자 인사이트를 활용하여 의사 결정에 반영하세요 | Do not know | Regional | Sometimes | 115043013133 |
| We represent the patient voice to mutual health insurance funds and within European consortia. | 의학 연구
> 의학 연구 | 근거 기반 환자 의견
> 환자 인사이트를 활용하여 의사 결정에 반영하세요 | 100 | National | Rarely | 115057856231 |
| Input from the patient organisation on reimbursement dossiers for new medications (via an extensive questionnaire). | 암
> 암: 폐 | 근거 기반 환자 의견
> 데이터 생성을 위한 설문조사/연구 수행 | 1,000 | Regional | Sometimes | 115039053506 |
| Since the introduction of a patient advisory process for the CTG [College Tarieven Gezondheidszorg - Healthcare Tariffs Authority] procedure in early 2025, we have compiled a submission dossier on two occasions. | 희귀
> 낭포성 섬유증 | 근거 기반 환자 의견
> 증거와 인사이트를 정책 입력으로 전환 | 1,000 | National | Sometimes | 115005093988 |
| Regional discussion on the cardiovascular prevention plan, with outreach to municipalities and CPAS [Centre Public d'Action Sociale – Public Centre for Social Welfare]. | 심혈관
> 심혈관: 대부분의 유형 | 진단 및 의약품 배달
> 검진 및 조기 발견 지원 | 100,000 | National | Regularly | 115042996911 |
| Working group on the new rare diseases plan, and various other working groups, committees, and similar bodies. | 희귀
> 희귀 질환: 대부분의 유형 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | We do not communicate with patients directly | National | Regularly | 115005882213 |
| At RIZIV [Rijksinstituut voor Ziekte- en Invaliditeitsverzekering – National Institute for Health and Disability Insurance], among other bodies. | 암
> 암: 혈액 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 1,000 | Regional | Regularly | 115010762888 |
| Through the Luss [Ligue des Usagers des Services de Santé – League of Health Service Users], which brings together several patient associations and has a member sitting on the Drug Reimbursement Committee at the INAMI [Institut National d'Assurance Maladie-Invalidité – National Institute for Health and Disability Insurance]. | 혈액
> 겸상 적혈구 질환 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | Do not know | National | Rarely | 115028443749 |
| Our association is an active member of various associations and organisations that regularly participate in advisory committees on this topic [drug pricing] (e.g. RaDiOrg, Rare Disorders Belgium & ERN [European Reference Network] Transplantchild). | 희귀
> 희귀 질환: 아동/청소년 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 100 | International | Sometimes | 115037392949 |
| Member of the steering committee for the national and regional plan. | HIV
> HIV 및 성 건강 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 100,000 | Regional | Sometimes | 115048515283 |
| On occasion, a subject-matter expert contributes through our overarching collaborative platform. | 류마티스성
> 류마티스 관절염 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 1,000 | Regional | Sometimes | 114998593281 |
| Working group on the new rare diseases plan, and various other working groups, committees, and similar bodies. | 희귀
> 희귀 질환: 대부분의 유형 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | We do not communicate with patients directly | National | Regularly | 115005882213 |
| I participate in the Observatoire des Maladies Chroniques [Observatory for Chronic Diseases] and in the work of the LUSS [Ligue des Usagers des Services de Santé – League of Health Service Users] (the umbrella body for patient associations), both of which address these subject areas. | 신경퇴행성
> 헌팅턴병 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 1,000 | National | Regularly | 115007525885 |
| We participate in stakeholder engagement sessions organised by Pharma.be and FAGG [Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten – Federal Agency for Medicines and Health Products]. | 혈액
> 혈액 질환: ITP | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 100 | National | Sometimes | 115021567311 |
| Through the Luss [Ligue des Usagers des Services de Santé – League of Health Service Users], which brings together several patient associations and has a member sitting on the Drug Reimbursement Committee at the INAMI [Institut National d'Assurance Maladie-Invalidité – National Institute for Health and Disability Insurance]. | 혈액
> 겸상 적혈구 질환 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | Do not know | National | Rarely | 115028443749 |
| [Working with] LUSS [Ligue des usagers des services de santé – League of Healthcare Service Users]. | 신경학적
> 섬유근육통 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 100 | National | Sometimes | 115028484320 |
| Patient expert for rare diseases, pharmaceutical companies, and other associations. | 희귀
> 희귀 질환: 신장 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 100 | National | Regularly | 115028704257 |
| Our association is an active member of various associations and organisations that regularly participate in advisory committees on this topic (e.g. RaDiOrg, Rare Disorders Belgium & ERN [European Reference Network] Transplantchild). | 희귀
> 희귀 질환: 아동/청소년 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 100 | International | Sometimes | 115037392949 |
| VPP [Vlaams Patiëntenplatform - Flemish Patients’ Platform] participates as a patient organisation in consultative platforms addressing key bottlenecks, such as reimbursement and temporary unavailability of medicines. Pricing policy is also covered within this remit. Through the ELZ [Eerstelijnszone – Primary Care Zone] P-Zon [Personen met een Zorg- en OndersteuningsNood - People with a Care and Support Need], we additionally ensure the patient voice is represented within the P-Zon cluster. | 신장
> 신장 질환 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 100 | Regional | Sometimes | 115055534359 |
| Patient consultation at AstraZeneca. | 암
> 암(남성): 유방 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 100 | Regional | Rarely | 115058978325 |
| Eligible to the EMA [European Medicines Agency] and invited to meetings and events, been part of regulatory evaluations. Member of EU HTA [Health Technology Assessment] stakeholder forum. | 신경퇴행성
> 헌팅턴병 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | Do not know | International | Sometimes | 119075658991 |
| I am currently in the process of re-establishing the association, and once it is fully operational, that is the objective. | 스킨
> 혈관부종 | 기관 거버넌스
> 공익 또는 자선 단체로서의 공식적인 지위 유지 | 100 | National | Sometimes | 115043847394 |
| Equal treatment for women and men with breast cancer. | 암
> 암(남성): 유방 | 환자 권리 보호/삶의 질 향상
> 환자 경험 보호/개선 | 100 | Regional | Sometimes | 115031895194 |
| Medications that are essential for the provision of quality palliative care are reviewed by us and designated for mandatory availability in local pharmacies. | 만성
> 완화 | 환자 권리 보호/삶의 질 향상
> 삶의 질 향상에 중점을 두는 것 | 1,000 | Regional | Sometimes | 115002049927 |
상호작용
활동 및 옹호
28 멘션
